Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126651 | 0.89 | CEL (0.46) | HTR2AHTR2CHTR2BTSHRMEN1 | |
| SCHEMBL24069104 | 0.89 | CEL (0.46) | HTR2AHTR2CHTR2BTSHRMEN1 | |
| SCHEMBL3794742 | 0.87 | OPRL1 (0.41) | HTR2AHTR2CHTR2BTSHRSLC6A3 | |
| SCHEMBL245508 | 0.86 | SLC6A2 (0.57) | HTR2CSLC6A3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL5584834 | 0.86 | HTR2A (0.42) | HTR2AHTR2CHTR2BTSHRMEN1 | |
| SCHEMBL3397657 | 0.84 | IDO1 (0.45) | HTR2AHTR2CHTR2BTSHRMEN1 | |
| SCHEMBL3773284 | 0.82 | DRD2 (0.50) | HTR2AHTR2CHTR2BMEN1KMT2A | |
| SCHEMBL2047547 | 0.82 | TAS1R3 (0.44) | HTR2AHTR2CHTR2BTSHRIDO1 | |
| SCHEMBL1897406 | 0.80 | TP53 (0.57) | HTR2AHTR2CHTR2BTSHRGRM2 | |
| SCHEMBL3785910 | 0.79 | SMN1; SMN2 (0.41) | HTR2AHTR2CHTR2BGRIA1CACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882722-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | Envoy Therapeutics Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014028479-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| CN-1934142-B | High-activity magnesium supported catalyst and method for preparing polyolefin by using same | LG CHEMICAL LTD | 2011-05-25 | — | — | CN | disclosed |
| EP-2283833-A2 | Amines and amides for the treatment of diseases | LA JOLLA PHARMACEUTICAL CO. (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-1807454-A1 | HIGH-ACTIVITY MAGNESIUM-SUPPORTED CATALYST AND METHOD OF PREPARING POLYOLEFIN USING THE SAME | LG Chem, Ltd. (KR) | 2007-07-18 | — | — | EP | disclosed |
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-05 | — | — | US | disclosed |
| CN-1934142-A | High-activity magnesium supported catalyst and method for preparing polyolefin by using same | LG CHEMICAL LTD (KR) | 2007-03-21 | — | — | CN | disclosed |
| EP-1732531-A2 | AMINES AND AMIDES FOR THE TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060111524-A1 | High-activity magnesium-supported catalyst and method of preparing polyolefin using the same | LG CHEM, LTD. (KR) | 2006-05-25 | — | — | US | disclosed |
| WO-2006049431-A1 | HIGH-ACTIVITY MAGNESIUM-SUPPORTED CATALYST AND METHOD OF PREPARING POLYOLEFIN USING THE SAME | LG CHEM, LTD. (KR) | 2006-05-11 | — | — | WO | disclosed |
| US-20060025438-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2006-02-02 | — | — | US | disclosed |
| WO-2005082343-A2 | AMINES AND AMIDES FOR THE TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC2, AOC1 | HTR2A 3494/4885HTR2C 4045/4885HTR2B 2767/4885 |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | VCAM1, AOC2, AOC1 | HTR2A 3494/4885HTR2C 4045/4885HTR2B 2767/4885 |
| US-20060025438-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC3, AOC2 | HTR2A 1447/4885HTR2C 2952/4885HTR2B 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.